News Archive

Every day on my way to work, I walk past the “Deepthroat Garage,” the once-secret spot where The Washington Post’s Bob Woodward met FBI Associate Director Mark Felt to swap info that eventually brought down President Richard Nixon in The Watergate scandal. It is a spot that resonates deeply with people in Washington, marked with a historical placard for those who are passing by.

There is another historical marker 100 feet from that location that is nowhere near as popular but arguably more significant. Across the intersection where Wilson and Clarendon boulevards meet marks the spot where the Internet was invented.

Imagine a world in which everyone is empowered to take charge of their own health care by discovering their personal genetic risk factors. That’s the vision of Anne Wojcicki, founder and CEO of the personalized gene-testing company 23andMe.

“How many people love the health care they’re getting today?” Wojcicki asked a large audience here Sunday (March 9) at the South By Southwest Interactive festival. Only a handful of people raised their hands.

Health technology startups shone this year at South by Southwest Interactive.

Pedicab bikers raved about TumorPaint (the inventor of the “molecular flashlight” delivered a rousing talk), and Misfit Wearables piqued excitement by giving out 100 of its free fitness devices to attendees. And a mental health startup called ThriveOn beat out social networking apps to win Best of Show at the accelerator competition.

Here’s a testament to how 3D printing is making rapid prototyping more accessible to startups and entrepreneurs. Pictured here is a smartphone case designed and 3D printed by 15-year-old Suman Mulumudi, a student at Lakeside School in Seattle (where Bill Gates attended).

Mulumundi is also the CEO of Stratoscientific, a company he co-founded with his father, a cardiologist, to commercialize the case and another cardiology device he developed.

Featuring Chris Sasiela, PhD, RAC, Regulatory Strategist, Office of Translational Alliances and Coordination, NHLBI, this inaugural Hangout, “Navigating the FDA website,” will provide biomedical innovators with an overview of the types of information available on the U.S. Food and Drug Administration website including: organization charts, contact info, guidance documents, and more!   Key take-away points will include: -A guide to finding organization charts for the FDA’s Center for Devices and Radiological Health, Center for Drug Evaluation and Research, and Center for Biologics Evaluation and Research -Contact information for various Offices and Divisions -Contact information for Small Business Assistance contacts -Guidance documents -Public information related to product approvals that can be applied to your technology   Tune in and share out using the hashtag #SBIRChat .

MIT professor Yael V. Hochberg revealed the most effective startup accelerators in the country Tuesday at SxSW in Austin. DreamIt Health showed up in slot #15 and was the only health focused accelerator on the list.

Hochberg is a professor of Finance at the Sloan School of Management at the Massachusetts Institute of Technology. She and professor Susan Cohen of the University of Richmond and the Batten Institute at the University of Virginia’s Darden School of Business, used original research and data from CrunchBase to rank the 15 accelerators.

Juxtopia®’s (www.juxtopia.org) team, Juxtopia® Imhotep, formed as a program to create minority telemedicine companies to address telemedicine marketplace needs. The global telemedicine market grew from $9.8 billion in 2010 to $11.6 billion in 2011 and will almost triple to $27.3 billion in 2016, a compound annual growth rate (CAGR) of 18.6% over the next five years, according to a report from BCC Research.

Juxtopia® Imhotep officially entered the Qualcomm Tricorder X PRIZE http://www.qualcommtricorderxprize.org/ in January, 2014. In this X PRIZE competition, Juxtopia® Imhotep will compete with 31 teams around the world to engineer a consumer-friendly mobile telemedicine device that will measure vital signs and diagnose 15 health conditions including, but not limited to, diabetes, anemia, atrial fibrillation, stroke, tuberculosis, chronic obstructive pulmonary disease (COPD), pneumonia, and hepatitis.

DreamIt Ventures continues its investment in the health tech space by launching its third DreamIt Health program. We’ve previously covered the 2013 DreamIt Health Philadelphia program and the 2014 DreamIt Health Baltimore program, which is ongoing. Applications for the third class, which will be in Philadelphia from July 18th till November 9th, are currently being accepted until May 16th. If you have the next great startup idea for health, you can apply here….

We had the opportunity to speak with DreamIt Health Managing Partner, Elliot Menschik, MD, PhD, about the program and where he sees opportunities in health tech entrepreneurship.

The IPO wave kept rolling for venture-capital-backed biotech as two life science companies held their first trading day Friday, while another estimated a price range for its public debut and a fourth publicly filed its paperwork.

Reuters Shares of Aquinox Pharmaceuticals Inc. rose 8.6%, while Recro Pharma Inc.‘s stock rose 3.8%.

To celebrate Women’s Day, we hobnobbed with 24 year-old Silicon Valley-based high-tech startup founder Meredith Perry. She’s audacious, persistent, resourceful and a game changer in every sense. Perry’s start-up, uBeam, develops technology using ultrasound to wirelessly charge devices. In 2012, Mike Arrington hailed her demo as the “closest thing to magic” he had seen in a long time. Since, Silicon Valley powerhouses such as Marissa Mayer, Peter Theil, and Andressen Horowitz have invested in uBeam.

Perry designed the early prototypes of uBeam’s technology without any engineering degree, relying on in-depth Internet research and “begging professors to teach her extra concepts after class.” When she first brought her idea to experts and engineers she was met with point-blank responses along the lines of ‘you are trying to do the impossible; it will never work.’